Monitored issues related to medical supply chain and pharmacy benefit management reforms. Monitored issues related to drug pricing. Issues regarding plasma-based therapies.
2026 · 3rd Quarter (July 1 - Sep 30)
CSL BEHRING LLC
Filed by THE NICKLES GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- THE NICKLES GROUP, LLC
- Client
- CSL BEHRING LLC
- Filing UUID
- ddd0b18b-e523-4854-aa2f-ebe4c92784da
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management reforms. Issues regarding plasma-based therapies. Issues related to Most Favored Nation drug pricing.
Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to foreign-based corporations, and corporate taxes. Issues related to the OECD Pillar II exemption for the U.S.
Literal federal measure citations: H.R. 1
Issues related to tariffs.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.